Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic adjuvant therapy for breast cancer

C A Hudis1, L Norton

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York City, NY 10021.

Current Opinion in Oncology
|November 1, 1993
PubMed
Summary

Systemic therapy after surgery lowers breast cancer recurrence and death risk. Identifying individual patient risk is key for tailoring treatments like polychemotherapy and tamoxifen.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parallel EEG-fNIRS assessments of covert cognition in behaviorally non-responsive ICU patients: A multi-task feasibility study in a case of acute motor sensory axonal neuropathy.

Journal of neurology·2025
Same author

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Relationships between older adults' use of time and cardio-respiratory fitness, obesity and cardio-metabolic risk: A compositional isotemporal substitution analysis.

Maturitas·2018

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Systemic therapy post-surgery reduces relapse and death in invasive breast cancer.
  • Established benefits of polychemotherapy and tamoxifen confirmed by collaborative group analysis.
  • Accurate individual risk stratification remains a challenge for treatment optimization.

Purpose of the Study:

  • To highlight the need for improved prognostic methods in breast cancer treatment.
  • To guide rational treatment recommendations based on individual patient risk.
  • To discuss the role of specific chemotherapies and dose intensity.

Main Methods:

  • Review of overview analysis by the Early Breast Cancer Trialists' Collaborative Group.
  • Discussion of prognostic factors (tumor size, lymph node status, histology).
  • Consideration of standard polychemotherapy regimens (CMF) and doxorubicin inclusion.

Main Results:

  • Low relapse risk for node-negative, small (<1 cm) tumors with no metastases.
  • Significant therapy benefits for node-negative patients with larger tumors or node-positive patients.
  • Doxorubicin justifiable in higher-risk patients (e.g., ≥4 positive lymph nodes).

Conclusions:

  • Improved prognostic methods are crucial for personalized breast cancer treatment.
  • Dose-intensification strategies are being explored to enhance relapse-free survival.
  • Tailoring therapy based on individual risk assessment optimizes treatment efficacy and minimizes toxicity.

Related Experiment Videos